AngioDynamics (NASDAQ:ANGO) CFO Stephen Trowbridge Sells 23,615 Shares of Company Stock

AngioDynamics, Inc. (NASDAQ:ANGO) CFO Stephen Trowbridge sold 23,615 shares of the business’s stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $12.27, for a total value of $289,756.05. Following the sale, the chief financial officer owned 280,461 shares of the company’s stock, valued at approximately $3,441,256.47. This trade represents a 7.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

AngioDynamics Price Performance

Shares of AngioDynamics stock opened at $11.99 on Friday. The stock has a market capitalization of $504.23 million, a P/E ratio of -15.37 and a beta of 0.30. The business has a 50 day simple moving average of $14.18 and a two-hundred day simple moving average of $12.47. AngioDynamics, Inc. has a 12 month low of $9.39 and a 12 month high of $16.29.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. The firm had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts anticipate that AngioDynamics, Inc. will post -0.26 EPS for the current fiscal year.

Hedge Funds Weigh In On AngioDynamics

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in AngioDynamics during the second quarter worth $49,480,000. Weber Capital Management LLC ADV purchased a new position in shares of AngioDynamics during the second quarter worth $17,649,392. Bastion Asset Management Inc. grew its stake in shares of AngioDynamics by 17.4% in the first quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock valued at $14,107,000 after buying an additional 194,822 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of AngioDynamics by 3.5% in the first quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock valued at $10,786,000 after buying an additional 32,476 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY acquired a new stake in shares of AngioDynamics in the second quarter valued at $8,732,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ANGO has been the topic of several recent research reports. HC Wainwright lowered their target price on AngioDynamics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Thursday, October 15th. Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Canaccord Genuity Group reissued a “buy” rating and set a $20.00 price objective on shares of AngioDynamics in a research note on Friday, October 9th. Finally, Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.00.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.

The company’s portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.